microdosing semaglutide for menopause Americans are obesity drugs, driven by 'thin is in' blitz Microdosing GLP-1 for Perimenopause: Why

Clinical evidence SELECT cardiovascular outcomes SELECT enrolled 17,604 adults aged 45 years with established atherosclerotic cardiovascular disease (prior MI, stroke, or symptomatic peripheral arterial disease) and BMI 27 kg/m, but without diabetes, randomizing them 1:1 to semaglutide 2.4 mg SC weekly (after titration) or placebo on top of standard CV therapies

Possible Adverse Reaction Semaglutide is generally well-tolerated, but some individuals may experience nausea, vomiting, constipation, and digestive discomfort

Recent studies have shown trizepatide tends to trigger the largest weight loss

During this stage, the medication helps support stability instead of continuing active weight loss

To build treatment plans, our clinicians use a metabolic health assessment called MetabolicPrint that uncovers the root causes of weight challenges to create a foundation for a personalized treatment plan